Register today: Anglonordic Life Science Conference 2026
As one of the organisers, Optimum is proud to partner with Anglonordic year on year to curate an awesome agenda for this fantastic event. Exclusively for European investors and R&D companies…
Hot topic: JPM 2026 – Deal or no deal – and does it matter?
JPM 2026 was touted as the event that would usher in the best year in biotech in a long time. But when it happened there was a distinct lack of mega-deals to shout about. The elephant, you might say, was not in the room. Does this bode ill for 2026? Or is news of such […]
Weekly roundup: Developments across Europe as positive JPM sets the tone for 2026
Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to the BioInnovation Institute (BII), a leading institute for life science and deep tech innovation in Copenhagen. The funding will enable BII to expand its activities into […]
Hot topic: Why Dry January is here to stay
There’s a temptation to think we won’t need Dry January or Love Your Liver Month initiatives in the future. After all, alcohol consumption is declining across the West and has been doing so for the last two decades. Gen Z teens rebel against their Gen X parents by not drinking – and castigating their elders for their unhealthy ways. In the UK only 7% […]
Weekly roundup: Kickstarting 2026 with financings, collaborations and clinical developments
Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation Acesion Pharma. a biotech company pioneering treatments for atrial fibrillation, the most common cardiac arrhythmia, announced enrolment of the first patients in its randomised, double-blind, placebo-controlled, dose finding Phase 2 clinical trial (NCT07267949), designed to assess the efficacy and safety of AP31969 […]
